Aspirin, warfarin and a thienopyridine for acute coronary syndromes

Yuval Konstantino, Zaza Iakobishvili, Avital Porter, Amir Sandach, Doron Zahger, Hanoch Hod, Haim Hammerman, Shmuel Gottlieb, Solomon Behar, David Hasdai

Research output: Contribution to journalArticlepeer-review

44 Scopus citations


Background: Although clopidogrel and aspirin (dual therapy, DT) are used for acute coronary syndrome (ACS), sometimes treatment with warfarin (triple therapy, TT) is required. Aim: To determine the incidence, complications, and outcomes of TT. Methods: We analyzed Israeli surveys of ACS from 2000 to 2004. Results: In these surveys, 5,706 (96%) were discharged alive from hospital. Post-ACS TT and DT were 76 patients (1.3%) and 2,661 patients (46.7%), respectively. The TT group was older with more prior cardiac disease. During hospitalization, the TT patients received more intravenous anticoagulant and antithrombotic agents, and had more heart failure, arrhythmias, ischemia, and major bleeding (2.6 vs. 0.6%, p = 0.03). There were no differences in adjusted 30-day and 6-month mortality between the 2 groups. Conclusion: TT is feasible among ACS patients who require concomitant warfarin treatment.

Original languageEnglish
Pages (from-to)80-85
Number of pages6
Issue number2
StatePublished - 1 Feb 2006
Externally publishedYes


  • Acute coronary syndromes
  • Aspirin
  • Bleeding
  • Clopidogrel
  • Mortality
  • Warfarin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)


Dive into the research topics of 'Aspirin, warfarin and a thienopyridine for acute coronary syndromes'. Together they form a unique fingerprint.

Cite this